Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky
Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the July 24, 2026 negative opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP"). NEW YORK, Aug. 3, 2026 /PRNewswire/ -- On July 24,...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.